Category: Pharma News
-
How LSD and classic psychedelics are re-entering modern psychiatry
Definium’s CMO talks about evaluating psychedelic medicine(s) in the modern era and developing novel treatments for mental health disorders.
-
Sensei Bio stock skyrockets on acquisition and $200m financing
Sensei stock surges after acquiring Faeth Therapeutics and securing $200 million private placement to advance cancer pipeline.
-
Canopy raises $22 million for healthcare safety platform
The Series B funding is expected to finance the expansion of Canopy’s connected safety platform across US health systems.
-
Eisai subsidiary starts Phase III trial for Schizophrenia drug in Japan
EA Pharma initiates a pivotal study of the novel glutamate modulator, evenamide, for treatment-resistant schizophrenia in Japan.
-
Endometriosis study uncovers molecular subgroups to guide trials
Endogene.bio’s research reveals how single-cell analysis predicts drug efficacy, enabling targeted treatments for endometriosis subgroups.
-
Secura Bio’s Copiktra PTCL data shines at ASH 2025
The company’s exec talks about how new analyses bolster the case for Copiktra in tough-to-treat lymphomas, informing a pivotal Phase III trial strategy.
-
FoRx secures $50 million to advance PARG inhibitor
Swiss biotech raises Series A financing to advance PARG inhibitor FORX-428, with initial clinical data expected in 2026.
-
Milestone Pharma wins FDA nod for self-administered nasal spray for PSVT
The at-home treatment is designed to manage acute symptomatic episodes outside of emergency healthcare settings.
-
AC Immune’s stock rises with positive Phase II data
Interim Phase II data suggest its vaccine candidate may slow progression, a potential first in Parkinson’s treatment.
-
ASH25: Tessera’s gene writing hits curative thresholds in sickle cell
New preclinical data show Gene Writing tech exceeding key efficacy benchmarks for sickle cell disease and in vivo CAR-T generation.
-
Dicot Pharma unlocks sustained ED effect with LIB-01
Swedish company reveals how LIB-01, an erectile dysfunction therapy, works via the melanocortin system, offering sustained effects and possible hope for non-responders.
-
Iolyx and Théa partner on $280 million autoimmune eye drug deal
Concurrently with the collaboration deal for ILYX-002 for autoimmune-associated dry eye disease, Iolyx announced a $15 million Series B financing.
Latest posts
-
How digital twins are pioneering a new era of personalized, longitudinal healthcare
Dr. Amanda Randles explains how they are developing digital twins to move medicine beyond static snapshots to dynamic, personalized care.
-
ASH25: Gallop’s LYT-200 shows unprecedented survival in AML
The company’s execs talk about the striking efficacy and safety signals seen in Phase I data, the science behind the molecule, and their vision for transforming AML therapy.
-
From data to desire: How Pharma learned to win the Super Bowl
Pharma marketing exec on how health brands are trading clinical claims for cultural currency—and what the FDA’s latest warning means for the future.
-
How LSD and classic psychedelics are re-entering modern psychiatry
Definium’s CMO talks about evaluating psychedelic medicine(s) in the modern era and developing novel treatments for mental health disorders.
-
How human organs are rewriting the rules of drug development
Dr. Jenna DiRito talks about why human organs may represent the “missing chapter” in our understanding of disease, and how this approach is already changing conversations with investors and regulators.